CRL

Business profile & competitive position

Charles River Laboratories International, Inc. (CRL) operates in the Healthcare sector, within the Medical - Diagnostics & Research industry. The company functions as a full-service, non-clinical global drug development partner, supplying research model technologies, discovery and safety assessment services—both GLP and non-GLP—and manufacturing support products and services. Operations are organized into three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. In 2025, total revenue was $4.0 billion, with DSA contributing 59.8%, RMS contributing 21.1%, and Manufacturing Solutions contributing 19.1%.

The current margin and return metrics do not point to strong near-term profitability. Net margin is -6.0% and return on equity is -7.7%. Both figures are negative, meaning the firm is currently spending more than it earns and is not generating a positive return for shareholders. A negative ROE of -7.7% indicates that whatever competitive position CRL holds in non-clinical services is not, at present, translating into excess economic returns. The market capitalization of $14.1 billion shows that investors still assign meaningful enterprise value, but the trailing accounting returns are under pressure.

Financial posture

CRL’s valuation reflects a loss-making yet asset-heavy enterprise. The market capitalization stands at $14.1 billion, while the trailing price-to-earnings ratio is -60.6, a direct consequence of negative trailing earnings. That negative P/E pairs with a net margin of -6.0% and an ROE of -7.7%, signaling that, as of the most recent data, the company is consuming capital rather than compounding it.

The stock also carries a beta of 1.41, implying historical price swings have been larger than those of the broader market. The current snapshot shows a share price of $293.455. The combination of a negative P/E, negative net margin, negative ROE, and elevated beta suggests the market is pricing CRL partly on a recovery or restructuring thesis rather than on current earnings power. No debt figure is supplied, so leverage cannot be assessed here.

Strategic priorities & outlook

The company’s most recent 10-K filing lays out several near-term priorities. First, CRL intends to optimize its global footprint by closing or consolidating approximately 12 additional sites over the next two years, principally in the DSA and RMS segments. Second, it is integrating Discovery Services and Safety Assessment into one overarching DSA organization with a combined sales force and leadership structure. Third, it aims to be the scientific partner of choice by delivering a comprehensive, integrated portfolio designed to accelerate biomedical research and therapeutic innovation. Fourth, it plans to continue expanding Biologics Testing Solutions service offerings and facilities in the United States and Europe.

Scale context matters: CRL currently operates more than 120 sites across more than 20 countries. The filing also notes that in January 2026 the company acquired certain assets of K.F. (Cambodia) Ltd., a provider of non-human primates, to support DSA supply operations and RMS third-party sales. These 10-K priorities connect directly to the 2030 plan management highlighted at its 2026 Investor Day on September 24, 2026—specifically, a 5%-7% growth target and $300 million in savings.

Macro & geopolitical exposure

CRL’s classification in Medical - Diagnostics & Research places it at the intersection of healthcare R&D funding, global regulation, and specialized supply chains. The business is exposed to biopharma R&D spending cycles because its clients are drug developers that outsource non-clinical work. Tighter capital markets or reduced biotech funding directly affect demand for discovery and safety assessment services.

Regulatory exposure is also material. GLP and non-GLP safety studies must meet FDA, EMA, and other health-authority standards, and animal-welfare rules add another layer of compliance risk. The company relies on research models and, as the January 2026 Cambodia acquisition indicates, on non-human primate supply chains. Trade policy has the potential to disrupt those supply chains, while currency fluctuations across more than 20 countries can move reported revenue and margins. Public health budgets, NIH funding, and broader healthcare policy are additional macro variables that can shift non-clinical research demand.

Recent developments

The most prominent recent event is CRL’s 2026 Investor Day on September 24, 2026. A businesswire.com headline that same day reported that Charles River highlighted a “refreshed strategic vision to drive profitable growth and long-term value creation.” A Seeking Alpha transcript published on September 24, 2026, captured the Analyst/Investor Day discussion. The following day, September 25, 2026, marketbeat.com summarized the 2030 plan: management is targeting 5%-7% growth and $300 million in savings. These three headlines describe a coordinated communications push around mid-term targets and operational streamlining.

A fourth headline, dated September 24, 2026, on defenseworld.net, offered a financial comparison between Charles River Laboratories (NYSE:CRL) and Adaptive Biotechnologies (NASDAQ:ADPT). That piece is less about CRL-specific news and more about peer benchmarking, but it reinforces the fact that investors are currently evaluating CRL against other diagnostics and research names.

Earnings behavior & post-earnings drift

CRL has delivered a perfect beat rate over the last eight reported quarters: 8 beats out of 8, with an average earnings surprise of 9.3%. That consistency is notable, but the stock’s short-term reaction to beats has been mixed. Across the same eight quarters, the average 5-day price move after earnings has been 1.24%, classified as an “up” drift.

The four most recent quarters illustrate the variability. On August 5, 2026, CRL reported EPS of $3.02 against the market’s real expectation of $2.74, a 10.2% surprise; the stock rose 1.84% the next day and 9.07% over the following five sessions. On May 7, 2026, EPS of $2.06 beat the $1.96 estimate by 5.1%, yet the stock fell 2.23% the next day and 12.42% over the following five days. On February 18, 2026, a $2.39 print versus a $2.33 estimate, a 2.6% surprise, produced a 3.95% one-day gain and a 6.05% five-day gain. On November 5, 2025, EPS of $2.43 beat the $2.32 estimate by 4.7%, with the stock rising 1.9% the next day and 2.27% over five days.

The next scheduled report is November 4, 2026, before the market opens, with a consensus EPS estimate of $2.96. The historical pattern shows CRL routinely exceeding the market’s real expectation, but the post-report price path is not uniform, and even beats have coincided with sharp short-term drawdowns.

For a deeper dive, explore the full institutional verdict on CRL to see how analysts are interpreting the 2030 plan, margin trajectory, and upcoming November 4, 2026 earnings report.